Go Deep
Viking Therapeutics, Inc.
Viking Therapeutics, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 16,349 | -6.1 | 8.88 | 0.01 | 2,757.31 |
| Oct 2026 | 16,396 | -6.1 | 8.83 | 0.01 | 2,713.29 |
| Oct 2026 | 16,860 | -5.7 | 8.30 | 0.01 | 2,537.98 |
| Oct 2026 | 17,181 | -5.5 | 7.93 | 0.01 | 2,418.31 |
| Oct 2026 | 16,664 | -6.1 | 8.52 | 0.01 | 2,599.08 |
| Oct 2026 | 17,262 | -5.4 | 7.84 | 0.01 | 2,383.98 |
| Oct 2026 | 17,295 | -5.4 | 7.80 | 0.01 | 2,375.15 |
| Oct 2026 | 16,844 | -5.7 | 8.32 | 0.01 | 2,532.55 |
| Oct 2026 | 16,933 | -5.6 | 8.22 | 0.01 | 2,495.08 |
| Oct 2026 | 17,083 | -5.5 | 8.04 | 0.01 | 2,438.11 |
Viking Therapeutics, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -128,022,000.0 | -158,325,000.0 | -157,662,000.0 | -90,787,000.0 |
| EPS | -1.1 | -1.4 | -1.4 | -0.8 |
Viking Therapeutics, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 | — |
| Net Profit | -359,639,000.0 | -109,963,000.0 | -85,895,000.0 | -68,867,000.0 | — |
| EPS | -3.2 | -1.0 | -0.9 | -0.9 | — |
Viking Therapeutics, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Total Assets | 715,729,000.0 | 908,321,000.0 | 368,490,000.0 | 168,529,000.0 |
| Total Liabilities | 76,667,000.0 | 28,043,000.0 | 20,071,000.0 | 23,207,000.0 |
| Total Equity | 639,062,000.0 | 880,278,000.0 | 348,419,000.0 | 145,322,000.0 |
Owes vs Owns
Viking Therapeutics, Inc. owed $0.22 for every $1 it owned in Jun 2026, up from $0.14 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.22× | 0.11× | 0.03× | 0.05× | 0.14× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Viking Therapeutics, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 98.6%Other assets 1.4%
How it's funded — Dec 2025
Payables 7.4%Other liabilities 3.3%Shareholders' equity 89.3%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 705.7 | 902.6 | 362.1 | 155.5 |
| Receivables | 0.0 | 0.0 | 0.0 | 0.0 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 0.1 | 1.0 | 1.1 | 1.4 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 9.9 | 4.7 | 5.3 | 11.6 |
| Liabilities & equity | ||||
| Short-term debt | 0.1 | 0.5 | 0.3 | 0.3 |
| Long-term debt | 0.0 | 0.6 | 0.9 | 1.3 |
| Payables | 53.3 | 9.8 | 7.5 | 8.5 |
| Other liabilities | 23.3 | 17.1 | 11.3 | 13.1 |
| Shareholders' equity | 639.1 | 880.3 | 348.4 | 145.3 |
| Net tangible assets | 639.1 | 880.3 | 348.4 | 145.3 |
Viking Therapeutics, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -278,685,000.0 | -87,790,000.0 | -73,376,000.0 | -48,397,000.0 | — |
| Investing Activities | 341,388,000.0 | -553,366,000.0 | -179,086,000.0 | 54,753,000.0 | — |
| Financing Activities | 76,439,000.0 | 612,464,000.0 | 271,376,000.0 | 4,163,000.0 | — |